Altex-Alternatives to Animal Experimentation

Papers
(The TQCC of Altex-Alternatives to Animal Experimentation is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Alternative Methods in Science: Towards Fluidic Systems51
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl128
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl518
Sensitivity analysis and quality indicators for an in vitro oral irritation assay16
Validation of an Endopep-suspension immunoassay for the diagnostics of human botulism_suppl15
Animal research ethics as interaction of research ethics, animal ethics, and (animal protection) law13
The effect of surfactants and film-forming polymers on pulmonary surfactant function measured in vitro is dose rate dependent_suppl10
Off to a good start? Review of the predictivity of reactivity methods modelling the molecular initiating event of skin sensitization9
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency9
REACH out-numbered! The future of REACH and animal numbers9
Intestinal in vitro transport assay combined with physiologically based kinetic modeling as a tool to predict bile acid levels in vivo_suppl19
Predicting Acute Oral Toxicity Using AcutoX: An Animal Product-Free and Metabolically Relevant Human Cell-Based Test9
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A8
Chemical selection for the Thyroid Validation Study coordinated by EURL ECVAM and involving EU-NETVAL laboratories_suppl17
E-validation – Unleashing AI for validation7
Making safety decisions for a sunscreen active ingredient using next-generation risk assessment: Benzophenone-4 case study7
Mapping out strategies to further develop human-relevant, new approach methodology (NAM)-based developmental neurotoxicity (DNT) testing7
Beyond Animal Testing Index: Benchmarking tool for a world beyond animal testing_suppl47
Stakeholder input towards further refinement and consolidation of the alternative safety profiling algorithm (ASPA) for next generation risk assessment (NGRA)_suppl26
Developmental neurotoxicity (DNT): A call for implementation of new approach methodologies for regulatory purposes: Summary of the 5th International Conference on DNT Testing6
Validation study for the evaluation of MCTT HCE™ test method for eye safety assessment of medical devices6
The long way from raw data to NAM-based information: Overview on data layers and processing steps6
Developing a global education hub for animal-free innovation_suppl6
Chemical selection for the Thyroid Validation Study coordinated by EURL ECVAM and involving EU-NETVAL laboratories_suppl35
Protectiveness of NAM-based hazard assessment – which testing scope is required?_suppl15
Exploring the synergy of CRISPR and microphysiological systems4
Chemical fate in vitro: A physiological biokinetic (PBK) model for cell-based assays_suppl34
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl24
AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting_suppl14
Non-animal approaches – Concept, validation, and regulatory acceptance: The fourth Asian Congress of Alternatives to Animal Experiments (4ACAAE) and the seventh Annual Meeting of the Society for Alter4
Lost in NAMs-lation: A review of animal-free science definitions4
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency_suppl64
3Rs: Progress or a fig leaf?4
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations4
Mapping physiology: A systems biology approach for the development of alternative methods in toxicology4
Investigation of the publication rate of recent research projects using non-human primates in France4
Low rejection rate for animal experiments in Germany despite legal reform3
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay_suppl33
The Virtual Human Platform for Safety Assessment (VHP4Safety) project: Next generation chemical safety assessment based on human data3
In vitro-based prediction of human plasma concentrations of food-related compounds_suppl13
Women in Alternatives3
The Alarming Consequences of Workforce Reductions at the FDA, EPA, NIH and CDC in the United States3
Chemical fate in vitro: A physiological biokinetic (PBK) model for cell-based assays_suppl23
Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARDskin dose-response assay3
Material-mediated pyrogens in medical devices: Myth or reality?_suppl22
Comparative evaluation of rat and human in vitro assays for evaluation of thyroid toxicity_suppl12
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl62
Qualitative and quantitative concentration-response modelling of gene co-expression networks to unlock hepatotoxic mechanisms for next generation chemical safety assessment2
Human relevant frontiers in drug safety and efficacy2
Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways2
A path forward advancing microphysiological systems2
Role of standards and funding in accelerating the development and use of microphysiological systems2
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis_suppl12
Building confidence in PBK model predictions in the absence of human kinetic data: Benzophenone-4 case study_suppl12
Second scientific sessions and international conference of the Society for Alternatives to Animal Testing in Sri Lanka (SAAT-SL)2
Micro-replace systems2
From cellular perturbation to probabilistic risk assessments2
ALTEX Proceedings TIERethik Corrigendum to Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment2
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl12
The SCAHT Adverse Outcome Pathway (AOP)_HUB: A hands-on platform for information exchange, sharing, and developing AOPs2
What does “success” look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations_suppl72
Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare2
Bridging the gap in chemical risk assessment: Leveraging metabolite similarity for enhanced read-across applications2
Transition to animal-free science: Phasing out animal experiments, phasing in innovation2
Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment2
Assessment of developmental neurotoxicology-associated alterations in neuronal architecture and function using Caenorhabditis elegans_suppl2
AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting1
A human iPSC-based in vitro neural network formation assay to investigate neurodevelopmental toxicity of pesticides_suppl21
Virtual control groups in non-clinical toxicology – A replicability challenge1
The benefits of validation of methods for toxicity testing outweigh its costs1
Advancing skin sensitization potency categorization using U-SENS™ in OECD TG 4971
3 Days for 3Rs 2023: Refinement, reduction, replacement1
Ways to broaden the awareness, consideration and adoption of new approach methodologies (NAMs)1
Data-driven derivation of an adverse outcome pathway linking vascular endothelial growth factor receptor (VEGFR), endocrine disruption, and atherosclerosis1
Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals_suppl21
A sensitive cell-based assay for testing potency of Botulinum neurotoxin type A_suppl1
The need for epigenotoxicity testing1
Towards NAM-based risk assessment for developmental neurotoxic effects, illustrated with chlorpyrifos1
International conference and workshop on “New Approach Methodologies (NAMs) in Pharmacology and Toxicology”1
Phase-out planning for animal experimentation: A definition, an argument, and seven action points1
Phasing in human-relevant science: Why the UK’s roadmap matters – and how to make it work1
Advancing humane and human-relevant science: The 8th Annual Conference of the Society for Alternatives to Animal Experiments – India (SAAE-I 2025)1
Material-mediated pyrogens in medical devices: Myth or reality?_suppl11
Impact of gut permeability on estimation of oral bioavailability for chemicals in commerce and the environment1
Guidance for Good In Vitro Reporting Standards (GIVReSt) – A draft for stakeholder discussion and background documentation1
Fish Count, Too – The Animal Toll of REACH Aquatic Toxicity Tests_suppl21
0.08690881729126